Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

NCT00179699 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00179699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00179699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Celgene Corporation
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2005
Completion date
November 30, 2006
Enrollment
40
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer